Mathew Leonardi: PCOS Has Been Renamed to PMOS and It Changes How We Understand the Disease
Mathew Leonardi, Associate Professor at McMaster University, shared a post on LinkedIn about a paper by Helena Teede et al. publsihed in The Lancet:
“PCOS has a new name: PMOS.
Polyendocrine Metabolic Ovarian Syndrome.
Honestly, I think this is a welcomed and important change. And the update deserves to be shared widely!
Every day in clinic, and at SUGO where we scan thousands of individuals, I see how much confusion the term ‘PCOS’ has created over the years. Patients are constantly told they either do or do not have the condition based mainly on whether their ovaries look ‘polycystic’ on ultrasound, when that has never been the full story. Many come in worried they have ‘ovarian cysts,’ others are reassured they cannot possibly have PCOS because their ovaries look normal, and meanwhile the broader hormonal and metabolic features of the condition are often missed or minimized.
The reality is that this has always been a far more complex endocrine and metabolic syndrome than the name suggested.
The updated term, PMOS, reflects that complexity much more accurately:
P for Polyendocrine, because multiple hormonal systems can be involved.
M for Metabolic, because insulin resistance and metabolic dysfunction are central features for many patients.
O for Ovarian, because the ovaries still matter, but are only one component of the condition.
S for Syndrome, because this does not present the same way in every individual.
One of the biggest misconceptions created by the old name is the idea that PCOS was fundamentally a disease of ‘ovarian cysts.’ In reality, what we typically see on ultrasound are multiple follicles, not pathologic ovarian cysts, and not every patient with the syndrome will even have classic ovarian morphology on imaging.
That misunderstanding has had real consequences. I see it constantly in practice. It contributes to delayed diagnosis, fragmented care, inappropriate reassurance, and patients feeling dismissed when their symptoms do not fit a narrow or outdated definition of the condition.
So while changing a name does not automatically fix gaps in care, terminology still matters. The language we use shapes how clinicians think, how patients understand their health, and how seriously a condition is taken.”
Title: Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
Authors: Helena J Teede, Mahnaz Bahri Khomami, Rachel Morman, Joop S E Laven, Anju E Joham, Michael F Costello, Madhuri Patil, D Aled Rees, Lorna Berry, Melanie G Cree, Han Zhao, Robert J Norman, Anuja Dokras, Terhi Piltonen, Global Name Change Consortium
Read the full article.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Nov 14, 2026, 19:27Katy Encalade: Coaching as an Investment in Ethical Leadership
-
Nov 14, 2026, 19:20Jeyarani Kamaraj: 9 Years of Waiting, 2 Heartbreaking Losses, And Today, 2 Tiny Hands to Hold
-
Nov 14, 2026, 19:12Lynn Burmeister: Why Doctor-Owned Fertility Clinics Matter
-
Nov 14, 2026, 18:36Alejandro González: Positive Test 4 Days After Blastocyst Transfer?
-
Nov 14, 2026, 18:29Danilo Cimadomo: Embryo Transfer Is a Means, Not the Objective Itself
-
Nov 14, 2026, 18:15Ryan Flynn: The Role of Psychosexual Medicine in Fertility Care
-
Nov 14, 2026, 18:04Khalil Faaed: Beyond the PB1 – Post-Denudation Oocyte Morphological Assessment in IVF and ICSI
-
Nov 14, 2026, 17:52Christopher Robinson: A Combined Treatment Strategy for Cesarean Scar Ectopic Pregnancy
-
Nov 14, 2026, 17:40Paul Pirtea: Does the Current Evidence Justify Routine Diagnosis and Treatment of Chronic Endometritis?